<DOC>
	<DOCNO>NCT02921997</DOCNO>
	<brief_summary>This single center , randomize , partially-blinded , Phase II , small , target , prospective study approximately 30 healthy male non-pregnant female subject age 18 49 year old , inclusive , design evaluate compare immunogenicity intramuscular monovalent inactivate influenza A/H7N9 virus vaccine give without AS03 adjuvant , intramuscular unadjuvanted monovalent inactivate influenza A/H3N2v virus vaccine . The primary objective include assess serum anti-HA hemagglutination-inhibition ( HAI ) response influenza A , identify differentially express gene human immune cell , identify differentially abundant cellular protein human immune cell .</brief_summary>
	<brief_title>Immunogenicity Monovalent Inactivated Influenza A/H7N9 Virus Vaccine .</brief_title>
	<detailed_description>This single center , randomize , partially-blinded , Phase II , small , target , prospective study approximately 30 healthy male non-pregnant female subject age 18 49 year old , inclusive , design evaluate compare immunogenicity intramuscular monovalent inactivate influenza A/H7N9 virus vaccine manufacture Sanofi Pasteur give without AS03 adjuvant manufacture GlaxoSmithKline , intramuscular unadjuvanted monovalent inactivate influenza A/H3N2v virus vaccine manufacture Sanofi Pasteur . The primary objective include assess serum anti-HA hemagglutination-inhibition ( HAI ) response influenza A/H7N9 antigen ( without adjuvant ) Day 57 ( approximately one month second study vaccination A/H7N9 vaccine ± AS03 ) influenza A/H3N2v antigen Day 29 , identify differentially express gene human immune cell Days 2 , 4 , 29 , identify differentially abundant cellular protein human immune cell Days 2 , 4 , 29 . The secondary objective compare plasma cytokine chemokine profile specific time point treatment arm post vaccination point , assess neutralize antibody response influenza A/H7N9 antigen , identify differentially express gene human immune cell Days 2 , 4 , 8 follow one intramuscular dose influenza A/H3N2v , identify differentially abundant cellular protein human immune cell Days 2 , 4 , 8 follow one intramuscular dose influenza A/H3N2v vaccine compare baseline assessment perform prior study vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Provide write informed consent prior initiation study procedure . 2 . Are able understand comply plan study procedure available study visit . 3 . Are male nonpregnant female , 18 49 year old , inclusive . 4 . Are good health . As determined medical history target physical examination , indicate base medical history , evaluate acute currently ongoing chronic medical diagnosis condition , define present least 90 day , would affect assessment safety subject immunogenicity study vaccination . Chronic medical diagnosis condition stable last 60 day . This include change chronic prescription medication , dose , frequency result deterioration chronic medical diagnosis condition 60 day prior enrollment . Any prescription change due change health care provider , insurance company , etc. , do financial reason , long class medication , consider deviation inclusion criterion . Any change prescription medication due improvement disease outcome , determine site principal investigator appropriate subinvestigator , consider deviation inclusion criterion . Subjects may chronic need ( prn ) medication , opinion site principal investigator appropriate subinvestigator , pose additional risk subject safety assessment reactogenicity immunogenicity indicate worsen medical diagnosis condition . Similarly , medication change subsequent enrollment study vaccination acceptable provide deterioration subject 's chronic medical condition necessitate medication change , additional risk subject interference evaluation response study vaccination . Note : Topical , nasal , inhaled medication ( exception inhale corticosteroid outline Subject Exclusion Criteria ( see Section 5.1.2 ) ) , herbal , vitamin , supplement permit . 5 . Oral temperature less 100.4F . 6 . Pulse 50 115 bpm , inclusive . 7 . Systolic blood pressure 85 150 mm Hg , inclusive . 8 . Diastolic blood pressure 55 95 mm Hg , inclusive . 9 . Erythrocyte sedimentation rate ( ESR ) less 30 mm per hour . 10 . Women childbearing potential 2 must use acceptable contraception method 3 30 day first study vaccination 60 day last study vaccination . Not sterilize via tubal ligation , bilateral oophorectomy , hysterectomy successful Essure® placement ( permanent , nonsurgical , nonhormonal sterilization ) document radiological confirmation test least 90 day procedure , still menstruate &lt; 1 year last menses menopausal . b . Includes , limit , nonmale sexual relationship abstinence sexual intercourse male partner , monogamous relationship vasectomize partner vasectomize 180 day prior subject receive first study vaccination , barrier method condom diaphragms spermicide foam , effective intrauterine device , NuvaRing® , license hormonal method implant , injectables oral contraceptive ( `` pill '' ) . 11.Women childbearing potential must negative urine serum pregnancy test within 24 hour prior study vaccination 1 . Have acute illness 4 , determine site principal investigator appropriate subinvestigator , within 72 hour prior study vaccination . a.Including acute chronic medical disease condition , define persist least 90 day would place subject unacceptable risk injury , render subject unable meet requirement protocol , may interfere evaluation response subject 's successful completion study . 2 . Have medical disease condition , opinion site principal investigator appropriate subinvestigator , contraindication study participation . a.Including acute chronic medical disease condition , define persist least 90 day would place subject unacceptable risk injury , render subject unable meet requirement protocol , may interfere evaluation response subject 's successful completion study 3 . Have immunosuppression result underlie illness treatment , use anticancer chemotherapy radiation therapy ( cytotoxic ) within 3 year prior study vaccination . 4 . Have know active neoplastic disease ( exclude nonmelanoma skin cancer ) history hematologic malignancy . 5 . Have know human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C infection . 6 . Have know hypersensitivity allergy egg , egg chicken protein , squalenebased adjuvant , component study vaccine . 7 . Have history severe reaction follow previous immunization license unlicensed influenza virus vaccine . 8 . Have personal family history narcolepsy . 9 . Have history GuillainBarré syndrome . 10 . Have history convulsion encephalomyelitis within 90 day prior study vaccination . 11 . Have history potentially immunemediated medical condition . 12 . Have history alcohol drug abuse within 5 year prior study vaccination . 13 . Have diagnosis , current past , schizophrenia , bipolar disease , psychiatric diagnosis may interfere subject compliance safety evaluation . 14 . Have hospitalize psychiatric illness , history suicide attempt , confinement danger self others within 10 year prior study vaccination . 15 . Have take oral parenteral ( include intraarticular ) corticosteroid dose within 30 day prior study vaccination . 16 . Have take highdose inhaled corticosteroid within 30 day prior study vaccination . Highdose define &gt; 840 mcg/day beclomethasone dipropionate CFC equivalent . 17 . Received licensed live vaccine within 30 day prior first study vaccination , plan receive license live vaccine within 30 day study vaccination . 18 . Received licensed inactivated vaccine within 14 day prior first study vaccination , plan receive license inactivated vaccine within 14 day study vaccination . 19 . Received immunoglobulin blood product ( exception Rho D immunoglobulin ) within 90 day prior study vaccination 20 . Received experimental agent7 within 30 day prior first study vaccination , expect receive experimental agent8 13month studyreporting period . Including vaccine , drug , biologic , device , blood product , medication . Other participation study . 21 . Are participate plan participate another clinical trial interventional agent9 receive 13month studyreporting period . Including license unlicensed vaccine , drug , biologic , device , blood product , medication . 22 . Prior participation clinical trial influenza A/H7 vaccine10 history influenza A/H7 virus actual potential exposure infection prior first study vaccination . assign group receive influenza A/H7 vaccine , apply document placebo recipient . 23 . Prior participation clinical trial influenza A/H3N2v vaccine11 history influenza A/H3N2v virus actual potential exposure infection prior first study vaccination . 24 . Occupational exposure substantial direct physical contact12 bird past year 28 day study vaccination . A.Casual contact bird pet zoos county state fair pet bird exclude subject study participation . 25 . Occupational exposure substantial direct physical contact13 pig past year 28 day study vaccination . a. Casual contact pig pet zoos county state fair exclude subject study 26 . Female subject breastfeed plan breastfeed give time first study vaccination 30 day last study vaccination . 27 . Plan travel outside US ( continental US , Hawaii , Alaska ) within 28 day study vaccination . 28 . Blood donation plan blood donation within 30 day enrollment 30 day last blood draw study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>April 5, 2017</verification_date>
	<keyword>A/H5N1</keyword>
	<keyword>A/H7N9</keyword>
	<keyword>ASO3 Adjuvant</keyword>
	<keyword>influenza</keyword>
	<keyword>monovalent</keyword>
	<keyword>pH1N1</keyword>
	<keyword>vaccine</keyword>
</DOC>